The collaboration will test Abbisko’s oral PD-L1 inhibitor lumipodlin with AstraZeneca’s Tagrisso in EGFR-mutated, PD-L1 positive locally advanced or metastatic non-small cell lung cancer in China.
verifying reliability
No specialized terms available for this topic.